VRAX — Virax Biolabs Cashflow Statement
0.000.00%
Last trade - 00:00- $4.41m
- -$2.50m
- $0.16m
- 50
- 28
- 40
- 33
Annual cashflow statement for Virax Biolabs, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.739 | -0.673 | -1.75 | -5.46 | -6.74 |
| Depreciation | |||||
| Non-Cash Items | 0.092 | 0.023 | 0.296 | 1.46 | 1.51 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.097 | 0.06 | 0.644 | -0.182 | -1.12 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.745 | -0.59 | -0.809 | -4.18 | -6.25 |
| Capital Expenditures | — | — | — | -0.178 | -1.16 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | — | — | — | -0.178 | -1.16 |
| Financing Cash Flow Items | 0.705 | 0.182 | 0.194 | -0.112 | -0.018 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.705 | 0.585 | 0.813 | 13.7 | 1.65 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.04 | -0.005 | 0.004 | 9.33 | -5.76 |